close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sorrento Therapeutics, Inc. - Common Stock (NQ:SRNE)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sorrento Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Sorrento Reports Encouraging Data From Sofusa-Administered Enbrel In Rheumatoid Arthritis ↗
Sorrento Therapeutics Inc (NASDAQ: SRNE) reported positive initial results from the Phase 1B study of its Sofusa Lymphatic Delivery System administering Amgen... 
Via Benzinga
News headline image
Market Briefing For Thursday, May 6 ↗
Wednesday was fairly stock specific (Peleton etc.), as well pharma, as the White House decided to vanquish vaccine IP rights, slapping those stocks counting on years-long revenue streams. Oils and... 
Via Talk Markets
News headline image
Market Briefing For Wednesday, May 5 ↗
Janet Yellen said 'interest rates may need to rise moderately', and that's a part of the backdrop, though S&P has been set-up for decline for awhile. 
Via Talk Markets
Topics Stocks
News headline image
Market Briefing For Wednesday, Apr. 28 ↗
Tactical behavior requires no change whatsoever. Just recognize that signs of an impending 'big-cap' correction are rising, with less erosion probably in a slew of small-cap stocks that have already... 
Via Talk Markets
News headline image
Sorrento To Start Testing STI-3031 In Patients With Advanced Urothelial Carcinoma ↗
The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE) IND to proceed with a Phase 2a study for STI-3031 for advanced urothelial carcinoma. STI... 
Via Benzinga
News headline image
Why Sorrento Therapeutics' Stock Is Trading Higher Today ↗
Sorrento Therapeutics (NASDAQ: SRNE) shares are trading higher after the company received FDA clearance to proceed with its Phase 2 study for Sti-3031 in advanced urothelial... 
Via Benzinga
News headline image
Why Sorrento Therapeutics Stock Is Soaring Today ↗
Hint: It's not because of anything the company said or did. 
Via The Motley Fool
News headline image
Cramer Shares His Thoughts On Ferrari, Palantir And More ↗
On CNBC's "Mad Money Lightning Round," Jim Cramer said Ferrari N.V. (NYSE: RACE) is just fabulous. He is a buyer of the stock. Cramer wouldn't hang around... 
Via Benzinga
News headline image
Market Briefing For Monday, Apr. 26 ↗
Nasdaq is perking up, primarily led by FANG types reporting next week (discounted). So, higher a bit near-term; then, risks. 
Via Talk Markets
News headline image
Sorrento's Human Derived Mesenchymal Stem Cells Achieves 100% Discharge Rate In Critically-Ill COVID-19 Patients ↗
Sorrento Therapeutics Inc (NASDAQ: SRNE) has announced data from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC)... 
Via Benzinga
News headline image
Market Briefing For Monday, April 19 ↗
Next week should see consolidation and upside, and then correction risk rises. We're cautious and looking for a setback, but not catastrophe ahead. 
Via Talk Markets
News headline image
Sorrento Therapeutics Stock Looks To Form Bullish Falling Wedge ↗
Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares lost ground Monday with no evident explanation. The stock was trending on StockTwits. Sorrento Therapeutics was down 7.... 
Via Benzinga
News headline image
Week In Review: Sorrento Acquires ACEA In $488 Million Deal Between Two San Diego-China Oncology Biopharmas ↗
Sorrento Therapeutics will acquire ACEA Therapeutics in a deal worth up to $488 million. Both companies develop novel cancer drugs, both are headquartered in San Diego and both have operations in... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today